The CCPG1 Knockout HT29 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the CCPG1 gene has been disrupted to create a loss-of-function model for studying cell cycle regulation and colorectal cancer biology. This polyclonal pool originates from the HT29 human colon adenocarcinoma cell line and retains a heterogeneous mixture of edited cells, enabling robust functional studies without clonal selection artifacts. The knockout population is designed for researchers requiring a reliable tool to interrogate G1/S transition control and the Cyclin D-CDK4/6-Rb signaling axis.
HT29 cells are an extensively characterized human colorectal adenocarcinoma line derived from a primary colon tumor, exhibiting epithelial morphology and retaining key features of intestinal differentiation. These cells are widely used as a model for colorectal adenocarcinoma, intestinal epithelial barrier function, and investigation of neoplastic signaling. The HT29 background offers a clinically relevant context for studying cell cycle dysregulation, as this line harbors mutations in APC, p53, and other cancer-associated genes, making it particularly suited for dissecting proliferative control mechanisms in colorectal malignancy.
CCPG1 (Cell Cycle Progression 1) functions as a critical facilitator of G1/S transition by interacting with the Cyclin D1-CDK4/6 holoenzyme. This interaction promotes efficient phosphorylation of the retinoblastoma protein (RB1), leading to derepression of E2F1 transcription factors and subsequent transcriptional activation of S-phase genes including Cyclin E and CDK2. Upstream signals from mitogenic growth factors such as EGF and HGF converge on Cyclin D1 expression and CDK4/6 activity, while the HSP70/HSP90 chaperone machinery supports CCPG1 stability and complex assembly. In the HT29 background, CCPG1-mediated coordination of these events is essential for maintaining proliferative capacity, and its disruption leads to RB1 hypophosphorylation, reduced E2F1 activity, and impaired cell cycle progression.
The knockout of CCPG1 in HT29 cells results in a significant impairment of G1/S transition, causing delayed or arrested cell cycle progression and reduced proliferation rates. This phenotype underscores the dependence of colorectal adenocarcinoma cells on intact CCPG1 function for sustained cell division. The polyclonal format preserves population-level heterogeneity, allowing investigators to study the collective impact of CCPG1 loss without confounding effects from clonal adaptation. This model is therefore highly relevant for exploring mechanisms of cell cycle dysregulation in colorectal cancer and for evaluating pharmacological inhibitors targeting CDK4/6 or upstream receptor tyrosine kinase signaling.
Research applications of this knockout product include detailed cell cycle profiling by flow cytometry using propidium iodide staining, EdU/BrdU incorporation assays to measure DNA synthesis, and colony formation or MTT assays to assess long-term proliferative capacity. Western blotting can be employed to monitor changes in phospho-RB1, Cyclin D1, and E2F1 expression, while RT-qPCR enables quantification of CCPG1, CCND1, and CDK4 transcript levels. The model supports anti-cancer drug screening, migration/invasion studies via transwell assays, and apoptosis detection with Annexin V staining. With its well-defined genetic background and versatile assay compatibility, the CCPG1 Knockout HT29 Polyclonal Cells serve as a powerful tool for mechanistic studies and therapeutic development in colorectal cancer. For further information, please contact Ascent Research.
